Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Other Non-Current Assets (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Other Non-Current Assets for 10 consecutive years, with $2000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Assets changed N/A to $2000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $2000.0, a N/A change, with the full-year FY2024 number at $2000.0, down 96.23% from a year prior.
  • Other Non-Current Assets was $2000.0 for Q3 2025 at Rein Therapeutics, roughly flat from $2000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $766000.0 in Q1 2025 to a low of $2000.0 in Q4 2024.
  • A 5-year average of $74285.7 and a median of $24000.0 in 2021 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: crashed 96.3% in 2021, then skyrocketed 112.0% in 2023.
  • Rein Therapeutics' Other Non-Current Assets stood at $24000.0 in 2021, then rose by 4.17% to $25000.0 in 2022, then surged by 112.0% to $53000.0 in 2023, then tumbled by 96.23% to $2000.0 in 2024, then changed by 0.0% to $2000.0 in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Other Non-Current Assets are $2000.0 (Q3 2025), $2000.0 (Q2 2025), and $766000.0 (Q1 2025).